DiShi Medical

DiShi Medical (迪视医疗) is a Hangzhou-based microsurgical robotics company founded in July 2021, developing supermicrosurgical robot systems with ophthalmic surgery as their entry point . The founding team came from top German robotics and AI labs and Fortune 500 German pharmaceutical companies, with CEO Cui Di (崔迪) having a background in biomedical research and pharma before returning to China to start the company . Linear Capital led their Pre-A round in early 2023 and has continued to back them through subsequent rounds, including a Pre-A+ in July 2023 and a near-100-million-RMB Series A in mid-2025 led by Panlin Capital .

Their flagship product, the "DiShi Weifeng" (迪视微锋) ophthalmic surgical robot, achieved 3-micron motion precision—among the highest internationally—and in July 2023 completed Asia's first retinal sub-thrombolysis surgery for macular hemorrhage at Zhejiang Provincial People's Hospital . By mid-2025, the product had become the first domestic ophthalmic surgical robot to enter NMPA's "green channel" for innovative medical devices, having completed registration clinical trials at multiple top-tier hospitals . The company has also been developing a general microsurgical robot platform with nearly 20 ultra-high degrees of freedom for applications across ENT, lymphatic surgery, neurosurgery, and plastic surgery .